Top Page
Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh
(Sydney:RMD)
Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh (RMD) vs. iShares MSCI Australia ETF (EWA)
Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh Business Overview & Revenue Model
Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh Earnings Call Summary
Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh Financial Statement Overview
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 5.26B | 5.15B | 4.69B | 4.22B | 3.58B | 3.20B |
| Gross Profit | 3.16B | 3.05B | 2.66B | 2.36B | 2.02B | 1.84B |
| EBITDA | 1.87B | 1.92B | 1.53B | 1.36B | 1.18B | 1.10B |
| Net Income | 1.44B | 1.40B | 1.02B | 897.56M | 779.44M | 474.50M |
Balance Sheet | ||||||
| Total Assets | 8.31B | 8.17B | 6.87B | 6.75B | 5.10B | 4.73B |
| Cash, Cash Equivalents and Short-Term Investments | 1.38B | 1.21B | 238.36M | 227.89M | 273.71M | 295.28M |
| Total Debt | 846.35M | 851.81M | 899.21M | 1.58B | 917.55M | 793.72M |
| Total Liabilities | 2.19B | 2.21B | 2.01B | 2.62B | 1.74B | 1.84B |
| Stockholders Equity | 6.12B | 5.97B | 4.86B | 4.13B | 3.36B | 2.89B |
Cash Flow | ||||||
| Free Cash Flow | 1.76B | 1.65B | 1.29B | 559.30M | 195.11M | 619.89M |
| Operating Cash Flow | 1.88B | 1.75B | 1.40B | 693.30M | 351.15M | 736.72M |
| Investing Cash Flow | -254.77M | -200.04M | -269.78M | -1.16B | -229.92M | -158.46M |
| Financing Cash Flow | -685.77M | -606.25M | -1.12B | 422.87M | -128.36M | -764.63M |
Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh Technical Analysis
Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh Risk Analysis
Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
77 Outperform | AU$53.63B | 24.30 | 26.73% | 0.94% | 11.99% | 32.89% | |
69 Neutral | AU$22.72B | 197.11 | 50.70% | 0.25% | 31.88% | 39.10% | |
69 Neutral | AU$16.85B | 43.35 | 20.11% | 1.67% | 4.32% | 9.24% | |
64 Neutral | AU$11.16B | 21.11 | 6.32% | 4.74% | 9.44% | -0.37% | |
54 Neutral | AU$7.95B | 1,168.92 | 0.38% | 2.32% | 6.82% | -99.27% | |
53 Neutral | AU$34.45B | 59.29 | ― | 0.43% | ― | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh Corporate Events
ResMed Inc has reported a change in beneficial ownership, with Peter C. Farrell, a director and significant shareholder, disposing of 2,000 shares of common stock at a price of $251.47 per share. This transaction, conducted under a pre-established Rule 10b5-1 plan, reflects ongoing adjustments in the company’s shareholder structure, potentially impacting investor perceptions and market dynamics.
ResMed Inc has filed a notice of proposed sale of securities under Rule 144, indicating the sale of 2,000 common shares with an aggregate market value of $502,860. The shares are to be sold by Peter C Farrell, a director of the company, and are scheduled for sale on December 3, 2025, on the NYSE. This transaction may impact the company’s stock liquidity and shareholding structure, potentially influencing investor perception and market dynamics.
ResMed Inc has announced an update regarding its CHESS Depositary Interests (CDIs), with a net increase of 918,810 CDIs over quoted securities for November 2025. This change is attributed to net transfers between CDIs and common stock, as well as activities related to stock options, restricted stock units, and employee stock purchase plans. The company also reported a decrease in other securities, reflecting strategic adjustments in its stock management, including share repurchases on the NYSE. These movements indicate ResMed’s ongoing efforts to optimize its capital structure and enhance shareholder value.
ResMed Inc. has announced a proposed sale of 1,000 common shares by Brett Sandercock, an officer of the company, under Rule 144 of the Securities Act of 1933. This transaction, set to occur on December 1, 2025, follows previous sales of 3,000 shares each in September, October, and November 2025, reflecting a strategic move by the officer to liquidate a portion of his holdings. The sale is valued at approximately $244,160 and will be conducted through Fidelity Brokerage Services LLC on the NYSE, indicating a continued trend of share sales by company insiders, which could have implications for investor perceptions and market dynamics.
Resmed Inc has filed a Form 144 with the SEC, indicating a proposed sale of 50 shares of common stock by Officer Michael J. Rider. The shares, acquired through restricted stock vesting, are set to be sold on December 1, 2025, on the NYSE with an aggregate market value of $12,208. This filing is part of a planned transaction under Rule 10b5-1, ensuring compliance with insider trading regulations. The sale is not expected to impact the company’s operations or market position significantly, as it represents a small fraction of the total shares outstanding.
ResMed Inc., a company known for its medical equipment and software solutions, has reported changes in beneficial ownership involving its director, Nicole Mowad-Nassar. The transaction involved the acquisition of 1,331 stock options at a price of $250.52, which will become exercisable by November 11, 2026, or earlier depending on the company’s annual meeting schedule. This transaction reflects strategic stock management and could influence stakeholder perceptions regarding the company’s governance and future performance.
Resmed Inc, a company listed on the NYSE, has filed a Form 144 for the proposed sale of securities under Rule 144 of the Securities Act of 1933. The filing indicates that Jan De Witte, a director of the company, plans to sell 2,055 shares of common stock, with an aggregate market value of $524,025. The shares were acquired through restricted stock vesting, with the sale expected to occur on November 25, 2025. This transaction reflects ongoing insider trading activities and may have implications for the company’s stock liquidity and market perception.
ResMed Inc., a company involved in the healthcare sector, focuses on providing innovative solutions for sleep apnea, chronic obstructive pulmonary disease, and other respiratory conditions. The recent announcement highlights a change in the company’s board, as Richard Sulpizio has ceased to serve as a director following the 2025 annual meeting of stockholders. This change in leadership may impact the company’s strategic direction and governance.
ResMed Inc.’s Chief Financial Officer, Brett Sandercock, reported a transaction involving the acquisition of 2,710 shares of ResMed common stock, which were performance-based restricted stock units earned upon meeting specific performance metrics. This transaction reflects the company’s commitment to aligning executive compensation with performance outcomes, potentially impacting stakeholder perceptions positively by demonstrating a focus on achieving strategic goals.
ResMed Inc. has reported changes in the beneficial ownership of its common stock by its Chairman and CEO, Michael J. Farrell. The report indicates that performance-based restricted stock units granted in 2022 were earned, and a portion of these shares was disposed of to cover tax obligations. This transaction reflects the company’s ongoing commitment to aligning executive compensation with performance metrics, potentially impacting investor perceptions and stakeholder confidence in the company’s leadership and strategic direction.
ResMed Inc. announced a change in beneficial ownership involving Peter C. Farrell, a director and significant shareholder of the company. Farrell acquired 536 shares of ResMed common stock, which were awarded as Restricted Stock Units (RSUs) that will vest in full by November 2026 or at the next annual stockholders’ meeting. This transaction reflects ongoing changes in the company’s ownership structure, potentially impacting shareholder dynamics and corporate governance.
ResMed Inc has reported changes in beneficial ownership involving its director, Carol Burt. The transaction involved the acquisition of 1,073 shares of ResMed common stock, with the shares awarded as Restricted Stock Units that will vest in full by November 2026 or at the next annual meeting of stockholders. This transaction highlights the company’s ongoing practices in stock-based compensation, which can impact shareholder value and executive incentives.
ResMed Inc, a company involved in the healthcare sector, has reported a change in beneficial ownership as per a recent filing. Jan De Witte, a director and 10% owner, acquired 1,073 shares of ResMed common stock through Restricted Stock Units (RSUs), which will vest in full by November 2026 or at the next annual stockholders’ meeting. This acquisition reflects the company’s ongoing commitment to aligning its leadership’s interests with those of its shareholders, potentially impacting its market positioning and stakeholder confidence.
ResMed Inc has reported a change in beneficial ownership as Director Christopher DelOrefice acquired 1,073 shares of common stock through Restricted Stock Units (RSUs) that vest by November 2026 or at the next annual stockholders’ meeting. This transaction reflects the company’s ongoing commitment to align its leadership’s interests with shareholder value, potentially impacting the company’s governance and stakeholder confidence.
ResMed Inc has reported a change in beneficial ownership as Harjit Gill, a director and 10% owner, acquired 1,073 shares of ResMed common stock through Restricted Stock Units (RSUs). These RSUs are set to vest in full by November 11, 2026, or at the next annual meeting of stockholders following the grant date. This transaction highlights the company’s ongoing efforts to align management interests with shareholder value, potentially impacting its market positioning and stakeholder confidence.
ResMed Inc. has reported a change in beneficial ownership, with Director Desney Tan acquiring 1,073 shares of ResMed common stock through Restricted Stock Units (RSUs). These RSUs are set to vest fully by November 11, 2026, or at the next annual stockholder meeting, indicating a strategic move to align management interests with shareholder value, potentially impacting investor confidence positively.
ResMed Inc has announced a change in beneficial ownership involving its director, Ronald Taylor, who acquired 1,073 shares of ResMed common stock. This transaction reflects a strategic move in the company’s governance and may influence its market positioning, as it involves the vesting of Restricted Stock Units (RSUs) that will fully vest by November 2026 or at the next annual stockholders’ meeting.
ResMed Inc has announced a change in beneficial ownership as reported by Nicole Mowad-Nassar, a director and 10% owner of the company. The transaction involved the acquisition of 536 shares of ResMed common stock, which were awarded as Restricted Stock Units (RSUs) set to vest in full by November 2026 or at the next annual meeting of stockholders. This move signifies a potential increase in insider confidence and may impact stakeholder perceptions positively, reflecting ongoing commitment to the company’s growth and stability.
ResMed Inc’s Chief Product Officer, Justin Leong, reported a transaction involving the acquisition of 1,848 shares of common stock, as detailed in a recent Form 4 filing. This transaction reflects the vesting of performance-based restricted stock units, indicating that the company’s performance metrics were successfully met, which may positively impact stakeholder confidence in ResMed’s operational and strategic execution.
ResMed Inc has reported a change in beneficial ownership as per a recent SEC Form 4 filing. John Hernandez, a director and significant shareholder, acquired 1,073 shares of ResMed common stock through Restricted Stock Units (RSUs), which will vest in full by November 2026 or at the next annual meeting of stockholders. This transaction reflects ongoing confidence in the company’s growth and strategic direction, potentially impacting investor sentiment positively.
ResMed Inc. has filed a registration statement on Form S-8 with the Securities and Exchange Commission to register an additional 3,000,000 shares for its 2018 Employee Stock Purchase Plan. This move is aimed at providing more opportunities for employees to purchase company stock, potentially enhancing employee engagement and aligning their interests with those of shareholders. The registration reflects ResMed’s ongoing commitment to its workforce and could have positive implications for its market positioning and stakeholder relations.
ResMed Inc. has filed a registration statement with the SEC to register an additional 2,400,000 shares for equity awards under its 2009 Incentive Award Plan. This move increases the total authorized shares for grants of equity awards to 14,337,229, reflecting the company’s commitment to incentivizing its workforce and potentially enhancing its market competitiveness.
ResMed Inc has reported changes in beneficial ownership, with Peter C. Farrell, a significant shareholder and Chairman emeritus, executing transactions involving the company’s common stock. The transactions include the automatic exercise of stock options and a disposition for tax withholding purposes, reflecting strategic financial management and potential impacts on shareholder value.
ResMed Inc has reported a change in beneficial ownership as per the recent SEC Form 4 filing. Director Harjit Gill disposed of a portion of ResMed common stock for tax withholding purposes related to the vesting of Restricted Stock Units. This transaction reflects routine financial management and is not expected to significantly impact the company’s operations or market positioning.
ResMed Inc, a company known for its medical devices and cloud-connected solutions for people with sleep apnea, chronic obstructive pulmonary disease, and other chronic diseases, has reported changes in the beneficial ownership of its common stock. The report indicates that Peter C. Farrell, a director and 10% owner, has disposed of some shares as part of a transaction under a pre-established Rule 10b5-1 plan. This transaction reflects a strategic financial decision possibly related to tax withholding obligations on vested Restricted Stock Units, which could impact the company’s stockholder dynamics and market perception.
ResMed Inc. has reported changes in beneficial ownership as per a recent SEC Form 4 filing. The company’s Chairman and CEO, Michael J. Farrell, disposed of shares to cover tax withholdings on the vesting of Restricted Stock Units granted in previous years. These transactions reflect routine administrative actions and are not expected to significantly impact the company’s operations or market positioning.
ResMed Inc, a company involved in the production of medical equipment, has reported changes in beneficial ownership by its director, Jan De Witte. On November 11, 2025, De Witte disposed of a portion of his common stock holdings in ResMed, with the transaction conducted under a pre-established Rule 10b5-1 plan. This move, which included a disposition for tax withholding purposes, reflects ongoing management of equity holdings by company insiders.
ResMed Inc has announced an update regarding the foreign exchange rate for its upcoming dividend distribution to holders of CHESS Depositary Interests (CDIs) on the Australian Securities Exchange (ASX). The exchange rate has been set at 0.6529 U.S. dollars for 1.00 Australian dollar, with dividends paid in Australian currency amounting to 0.0919 Australian dollars per CDI. The default U.S. withholding tax is 30%, but it can be reduced to 15% under the U.S.-Australia tax treaty if the necessary forms are submitted. This update reflects the company’s ongoing financial operations and its commitment to maintaining transparency with its investors.
ResMed Inc. has reported changes in the beneficial ownership of its common stock by Michael J. Rider, the company’s Global General Counsel. The transactions, which occurred on November 11, 2025, involved the disposition of shares to the issuer for tax withholding on the vesting of Restricted Stock Units granted in previous years. This update reflects standard corporate governance practices and is not expected to significantly impact ResMed’s market position or stakeholder interests.
ResMed Inc. has filed a Form 144 notice for the proposed sale of 487 shares of common stock by its director, Jan De Witte. The shares, valued at approximately $121,871.75, are set to be sold on the NYSE on November 11, 2025. This transaction involves restricted stock vesting as part of compensation, and there are no reported sales of the issuer’s securities in the past three months. The filing indicates compliance with Rule 144 under the Securities Act of 1933, ensuring transparency and adherence to regulatory requirements.
ResMed Inc has announced a proposed sale of 2,000 common shares by Peter C Farrell, a director of the company, under Rule 144 of the Securities Act of 1933. The sale, valued at approximately $504,100, is scheduled to occur on November 12, 2025, on the NYSE. This transaction reflects a routine financial decision by an insider and does not indicate any undisclosed adverse information about the company’s operations or future prospects.
ResMed Inc.’s Chairman and CEO, Michael J. Farrell, reported changes in beneficial ownership, involving transactions of common stock and stock options under a pre-established Rule 10b5-1 plan. The transactions reflect strategic financial management by the executive, with implications for the company’s stock performance and stakeholder interests, as they involve the acquisition and sale of shares at specified prices.
ResMed Inc. has filed a notice of proposed sale of securities under Rule 144, indicating that Michael J. Farrell, an officer and director of the company, plans to sell 8,011 shares of common stock. The aggregate market value of these shares is approximately $2,000,773.19, with the sale expected to take place on November 7, 2025. This transaction follows previous sales by Farrell in the past three months, reflecting ongoing insider trading activities that stakeholders may need to monitor for potential impacts on stock performance and market perception.
ResMed Inc.’s Chief Financial Officer, Brett Sandercock, reported a change in beneficial ownership of the company’s common stock. On November 3, 2025, Sandercock acquired 2,000 shares through stock options at a price of $101.64 per share and disposed of 3,000 shares at $247.54 per share. This transaction was conducted under a Rule 10b5-1 plan, indicating a pre-planned trading strategy. The change in ownership reflects ongoing management of equity holdings by the company’s executive, which may impact investor perceptions and the company’s stock performance.
Resmed Inc announced a net decrease of 3,891,110 CHESS Depositary Interests (CDIs) issued over quoted securities for October 2025, attributed to net transfers between CDIs and common stock on the NYSE. Additionally, there was an increase in securities not issued as CDIs, driven by new share issues related to stock options, restricted stock units, and employee stock purchase plans, as well as share repurchases on the NYSE. This adjustment in securities reflects Resmed’s ongoing management of its capital structure and may impact its market positioning and stakeholder interests.
ResMed Inc. has filed a notice for the proposed sale of securities under Rule 144, indicating that Brett Sandercock, an officer of the company, plans to sell 3,000 shares of common stock. The aggregate market value of these shares is approximately $742,620, with the sale expected to occur on November 3, 2025. This transaction follows a previous sale of 3,000 shares by Sandercock in September 2025, which yielded gross proceeds of $812,310. The announcement reflects ongoing insider trading activities and may impact stakeholder perceptions regarding the company’s stock performance.
ResMed Inc. has filed its quarterly report for the period ending September 30, 2025, indicating compliance with the Securities Exchange Act of 1934. The report highlights the company’s financial performance and operational updates, providing stakeholders with insights into its market positioning and strategic initiatives. The filing confirms ResMed’s status as a large accelerated filer, reflecting its significant market presence and operational scale.
ResMed Inc. has reported changes in the beneficial ownership of its securities, as disclosed in a recent filing. Brett Sandercock, the company’s Chief Financial Officer, executed transactions involving the acquisition and disposal of ResMed common stock under a pre-established Rule 10b5-1 trading plan. These transactions reflect ongoing strategic financial management and compliance with regulatory requirements, potentially impacting investor perceptions and market dynamics concerning ResMed’s stock.
ResMed Inc’s Global General Counsel, Michael J. Rider, reported a transaction involving the disposal of 100 shares of ResMed common stock on October 1, 2025, at a price of $274.36 per share. This transaction was conducted under a pre-established Rule 10b5-1 trading plan, which allows company insiders to sell stocks at predetermined times to avoid accusations of insider trading. The transaction reflects a strategic financial decision by the company’s executive, potentially impacting the perception of the company’s stock value among stakeholders.
ResMed Inc. announced an increase in the number of CHESS Depositary Interests (CDIs) issued over quoted securities, with a net addition of 3,066,120 CDIs in September 2025. This change is attributed to net transfers between CDIs and common stock, as well as activities related to stock options and employee stock plans. The company also reported a decrease in the number of securities over which CDIs have not been issued, due to share repurchases and new share issues on the NYSE.
ResMed Inc. has announced its 2025 Annual Meeting, scheduled for November 19, 2025, in the US and November 20, 2025, in Australia. The meeting will be conducted virtually, allowing shareholders to participate and vote on various proposals. This announcement is significant as it emphasizes the company’s commitment to shareholder engagement and transparency, providing stakeholders with the opportunity to influence corporate governance and strategic decisions.
Resmed Inc has filed a definitive proxy statement with the United States Securities and Exchange Commission, indicating no fee is required for this filing. This filing is part of the company’s compliance with the Securities Exchange Act of 1934, and it does not appear to have immediate implications for the company’s operations or stakeholders.
Resmed Inc has filed a notice for the proposed sale of securities under Rule 144, with Brett Sandercock, an officer of the company, planning to sell 3,000 shares of common stock. The transaction, which involves securities acquired through restricted stock vesting and options granted, reflects a strategic decision by the officer, potentially impacting the company’s stock liquidity and market perception.
Resmed Inc has announced a proposed sale of securities under Rule 144, involving the sale of 8,009 common shares by Michael J. Farrell, an officer and director of the company. The transaction, facilitated through Fidelity Brokerage Services LLC, is set to take place on September 8, 2025, with an aggregate market value of approximately $2,227,590.84. This sale follows previous transactions by Farrell within the past three months, reflecting a strategic decision that may impact the company’s stock liquidity and stakeholder interests.